How much is Arcosa worth?
Arcus Biosciences, Inc. commands a corporate market capitalization of approximately $3.36 billion USD (or roughly ₹367.67 billion). As a clinical-stage biopharmaceutical company focused on creating innovative cancer immunotherapies, its market valuation fluctuates continuously during active trading hours based on clinical trial milestones, research collaboration developments, regulatory updates, and periodic healthcare sector market sentiment trends tracked by biotechnology investors.
Related FAQs
Aristocrat Leisure generates revenue primarily by manufacturing gaming machines, designing games, and providing gaming systems and consulting services.
Aedifica has maintained a solid financial performance, anchored by its robust portfolio of European healthcare real estate assets, strategic asset rotation initiatives, and disciplined capital management.
Arcus Biosciences, Inc. maintains a specialized biotechnology workforce of approximately 600 employees.
Executive compensation for Michael Arougheti, serving as the Chief Executive Officer of Ares Management Corporation, reflects elite leadership within the global alternative investment management sector.
Arcosa, Inc., which trades on the New York Stock Exchange under the ticker symbol ACA, is a fully transparent, publicly traded corporation.
Arcosa operates as a fully public corporate entity, listed and traded on the New York Stock Exchange under the ticker symbol ACA.